A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

NCT07034508 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

134

Enrollment

OTHER

Sponsor class

Conditions

DLBCL - Diffuse Large B Cell Lymphoma

Interventions

DRUG: Polatuzumab Vedotin
DRUG: Rituximab
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Prednisone

Sponsor

Institute of Hematology & Blood Diseases Hospital, China